Bone metastases in prostate cancer – Gallium-68–labeled prostate-specific membrane antigen or Fluorine 18 sodium fluoride PET/computed tomography – the better tracer?-Reference-Cited by-同舟云学术

Bone metastases in prostate cancer – Gallium-68–labeled prostate-specific membrane antigen or Fluorine 18 sodium fluoride PET/computed tomography – the better tracer?

Published:2022-10-19 Issue:12 Volume:43 Page:1225-1232
ISSN:0143-3636
Container-title:Nuclear Medicine Communications
language:en
Short-container-title:

Author:

Agrawal Archi,Natarajan Aravintho,Mithun Sneha,Bakshi Ganesh,Joshi Amit,Murthy Vedang,Menon Santosh,Purandare Nilendu,Shah Sneha,Puranik Ameya,Choudhury Sayak,Prakash Gagan,Pal Mahendra,Maitre Priyamvada,Prabhash Kumar,Noronha Vanita,Rangarajan Venkatesh

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference28 articles.

1. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis.;Lipton;Bone,2011

2. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer.;Halabi;J Clin Oncol,2016

3. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer.;Pollen;Am J Roentgenol,1984

4. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).;Eisenhauer;Eur J Cancer,2009

5. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.;Afshar-Oromieh;Eur J Nucl Med Mol Imaging,2015

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: positive pitfalls of PSMA PET/CT: diagnostic challenges in degenerative bone lesions including MODIC type 1;Frontiers in Nuclear Medicine;2024-08-02

2. PSMA PET/CT for Primary Staging of Prostate Cancer - An Updated Overview;Seminars in Nuclear Medicine;2024-01

3. Bone Metastasis in Prostate Cancer: Bone Scan Versus PET Imaging;Seminars in Nuclear Medicine;2024-01

4. Les radiotraceurs autres que le PSMA-ligand pour l’imagerie TEP du cancer de prostate;Médecine Nucléaire;2023-10